Nabriva therapeutics appoints CEO
This article was originally published in Scrip
Executive Summary
Biotechnology company Nabriva Therapeutics, which is developing a new class of antibiotics for the treatment of serious infections caused by resistant gram-positive and gram-negative pathogens, has named Dr Colin Broom chief executive officer. Prior to joining Vienna-based Nabriva Dr Broom was chief scientific officer at ViroPharma, which was acquired by Shire in January 2014. He succeeds Ralf Schmid, who will remain at the company as a member of the executive management team and will move to the role of chief financial officer and chief operating officer.